Navigation Links
Genedata Screener to Present at 10th Annual Ion Channel Retreat
Date:6/25/2012

Vancouver, Canada (PRWEB) June 25, 2012

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata Screener® for Ion Channel Screening will be a featured presentation at the 10th Annual Ion Channel Retreat. The Retreat showcases new screening technologies and the importance of improving the safety of target compounds. The Genedata presentation will show how to overcome current issues in Ion Channel data analysis on real-life examples using Genedata Screener for Ion Channel Screening.

The new Genedata Screener for Ion Channel Screening is a first-in-class Ion Channel screening solution that enables scalable and automated data analysis. The software’s exceptional data loading and processing speed combined with the ability to simultaneously process multiple plates significantly reduces analysis time. Part of the Retreat’s Ion Channel Screening session, the Genedata presentation will highlight analyses of two distinct datasets from leading pharmaceutical companies that collaborate with Genedata.

Presentation Highlights
Today’s electrophysiology experiments measure simultaneously 1000s of compounds and 100,000s of data points per day, producing gigabytes of raw data – for which the data analysis renders a severe bottleneck. Genedata Screener’s streamlined data analysis workflows for microfluidics-based Automated Patch Clamp (APC) experiments increase the sample throughput and the level of detail in biological characterizations. The Genedata session will present a case study that:

  •     Overviews typical challenges in APC data analysis
  •     Discusses specific problems in uncovering relevant biological effects
  •     Demonstrates single- and multi-compound workflows that mitigate data analysis risks
  •     Provides examples on how analysis time can be reduced and result quality improved with automated analysis workflows

Genedata Screener for Ion Channel Screening easily integrates into corporate screening data analysis environments, and imports data from various well/plate instruments including Fluxion Ionflux™ and MD IonWorks® Quattro™ and Barracuda™.

“With the latest innovations in miniaturization and automation, screening instrumentation now enables parallel testing applying innovative technologies such as APC, which results in data of unprecedented volume, complexity, and value,” said Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Screener for Ion Channel Screening, we enable scientists to take advantage of these technologies by empowering them to efficiently analyze and interpret this data. Our support of Automated Electrophysiology underscores the Genedata commitment to advanced screening technologies such as High Content and Label-Free screening.”

NOTE: The Genedata session --“High-volume data analysis workflows for microfluidics-based automated patch clamps” -- will be presented by Dr. Stephan Steigele on June 27 at 3:00pm EDT. To schedule a briefing email: jackie.thrasivoulos (at) genedata (dot) com.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. http://www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/Ion_channel_screening/Genedata_Screener/prweb9626890.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. In Comes the Non-Toxic Rust Remover; Rusterizer Presents Its Rust Removal Product Made With Natural Ingredients
2. Dads get Present from Rusterizer, Company Marks Down its Rust Remover by 27%
3. Northeastern University Nanomanufacturing Center Director Ahmed Busnaina to Present Webinar on “The Democratization of Manufacturing”
4. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
5. NYSE Companies and NASDAQ Companies June 7th Investor Presentations Now Available at RetailInvestorConferences.com
6. Fusion presents low proliferation risk, experts conclude
7. Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
8. Luminex Corporation to Present at Jefferies 2012 Global Healthcare Conference
9. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
10. Watson to Present at Goldman Sachs Global Healthcare Conference 2012
11. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, Inc. ... company, today announced that Richard Peterson will ... 24.   Peterson, who brings more than two ... Smither , who is retiring at the end of ... advisory capacity. Peterson joins Sienna from Novan, Inc., where ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
(Date:3/23/2017)... ... 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), a ... “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will lead ... Floyd’s career has spanned 30 years in the chemicals and equipment industries. Sig ...
Breaking Biology Technology:
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
(Date:3/6/2017)... 6, 2017 Mintigo , the ... announced Predictive Sales Coach TM , its new ... intelligence into Salesforce. This unique AI application will ... organizations with deep knowledge of their customers and ... engagement. Predictive Sales Coach extends Mintigo,s existing customer ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
Breaking Biology News(10 mins):